Sarepta Names Ian Estepan President and COO Amid Restructuring

Sarepta has appointed Ian Estepan as President and Chief Operating Officer, Louise Rodino-Klapac as President of Research & Development and Technical Operations, Ryan Wong as Chief Financial Officer, Rachael Potter as Chief Scientific Officer, and Patrick Moss as Chief Commercial Officer. The restructuring follows the departure of Dallan Murray, Chief Customer Officer.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has announced a significant leadership change as part of its ongoing strategic restructuring. The company has appointed Ian Estepan as President and Chief Operating Officer, Louise Rodino-Klapac as President of Research & Development and Technical Operations, Ryan Wong as Chief Financial Officer, Rachael Potter as Chief Scientific Officer, and Patrick Moss as Chief Commercial Officer. This restructuring follows the departure of Dallan Murray, who served as Chief Customer Officer [1].

The appointments are part of Sarepta's broader strategic plan to prioritize high-impact programs and ensure long-term financial viability. The company aims to reduce operating expenses and align its cost structure with strategic priorities, with a focus on the siRNA platform [1]. The new leadership team will play a crucial role in implementing these changes and driving the company's pipeline of rare genetic disease therapies forward.

Louise Rodino-Klapac, who previously served as the Senior Vice President of Research Sciences, will lead the research and development efforts. Her appointment reflects Sarepta's commitment to advancing its potentially best-in-class siRNA platform and exploring new therapeutic areas [1]. Ian Estepan, who was previously the Chief Operating Officer of a biotechnology company, will oversee day-to-day operations and ensure the company's strategic priorities are met.

Ryan Wong, who was previously the Senior Vice President of Strategic Finance, Treasury, and Investor Relations, will serve as the Chief Financial Officer. His appointment underscores Sarepta's focus on financial management and its goal of maintaining robust cash flow to manage liabilities, including the repayment of the 2027 convertible note [1].

Rachael Potter, who was previously the Senior Vice President of Research Sciences, will serve as the Chief Scientific Officer. Her appointment highlights Sarepta's commitment to scientific innovation and its efforts to advance genetic medicine [1]. Patrick Moss, who was previously the Senior Vice President of U.S. Market Access and Sales, will lead commercial operations. His appointment reflects Sarepta's focus on driving performance of its Duchenne therapies and associated clinical trial commitments.

Sarepta's strategic restructuring and leadership changes are designed to position the company for long-term sustainable growth and ensure its ability to deliver on its mission of advancing innovative medicines for those with rare genetic diseases [1]. The company will host an investor call on July 16, 2025, at 4:30 p.m. Eastern time, to discuss these updates [1].

References:
[1] https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-strategic-restructuring-and